103 related articles for article (PubMed ID: 23085831)
21. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
22. [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
Nakamura Y; Mori T; Kato J; Aisa Y; Nakazato T; Shigematsu N; Okamoto S
Rinsho Ketsueki; 2012 Mar; 53(3):318-22. PubMed ID: 22499048
[TBL] [Abstract][Full Text] [Related]
23. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Waterman J; Rybicki L; Bolwell B; Copelan E; Pohlman B; Sweetenham J; Dean R; Sobecks R; Andresen S; Kalaycio M
Bone Marrow Transplant; 2012 Apr; 47(4):488-93. PubMed ID: 21572461
[TBL] [Abstract][Full Text] [Related]
25. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
[No Abstract] [Full Text] [Related]
26. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
27. Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
Yanagisawa R; Nakazawa Y; Sakashita K; Tanaka M; Shikama N; Kamijo T; Shiohara M; Koike K
Pediatr Transplant; 2009 Sep; 13(6):737-45. PubMed ID: 19207225
[TBL] [Abstract][Full Text] [Related]
28. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X
Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720
[TBL] [Abstract][Full Text] [Related]
29. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.
Kharfan-Dabaja MA; Otrock ZK; Bacigalupo A; Mahfouz RA; Geara F; Bazarbachi A
Bone Marrow Transplant; 2012 Sep; 47(9):1254-5. PubMed ID: 22246089
[No Abstract] [Full Text] [Related]
30. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
31. Successful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopenia.
Hamidieh AA; Pourpak Z; Hamdi A; Nabavi M; Ghavamzadeh A
Pediatr Transplant; 2013 Jun; 17(4):E109-11. PubMed ID: 23581828
[TBL] [Abstract][Full Text] [Related]
32. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
33. Regurgitation of esophageal mucosa.
Gesundheit B; Resnick IB
Mayo Clin Proc; 2007 Aug; 82(8):907. PubMed ID: 17673057
[No Abstract] [Full Text] [Related]
34. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
Corker E; Astwood E; Williams J; Vora A
Br J Haematol; 2012 Oct; 159(1):104-6. PubMed ID: 22804487
[No Abstract] [Full Text] [Related]
35. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
36. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
38. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
Kornguth DG; Mahajan A; Woo S; Chan KW; Antolak J; Ha CS
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1140-4. PubMed ID: 17379444
[TBL] [Abstract][Full Text] [Related]
40. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
